Predictors of survival in systemic sclerosis (scleroderma).

We conducted followup of 264 patients with definite systemic sclerosis (SSc) who were entered into the multicenter Scleroderma Criteria Cooperative Study (SCCS) during 1973-1977. At the end of the study (average 5.2 years of followup), 38% were known to be alive, 50% were dead (68% of these deaths definitely related to SSc), and 12% were lost to followup. Survival analyses of 484 demographic, clinical, and laboratory items recorded at entry into the SCCS (within 2 years of physician diagnosis of SSc) were performed. Survival declined linearly, and the cumulative survival rate was less than 80% at 2 years, 50% at 8.5 years, and 30% at 12 years after entry. Analysis using combinations of entry variables identifying organ system involvement confirmed that renal, cardiac, pulmonary, and gastrointestinal involvement in SSc predicted reduced survival; however, data on organ system involvement at study entry could not be used to consistently predict which organ system would ultimately be involved as the primary cause of death. By survival tree analysis, the individual entry variables best predicting reduced survival included older age (greater than 64 years), reduced renal function (blood urea nitrogen greater than 16 mg/dl), anemia (hemoglobin less than or equal to 11 gm/dl), reduced pulmonary diffusing capacity for carbon monoxide (less than or equal to 50% of predicted), reduced total serum protein level (less than or equal to 6 gm/dl), and reduced pulmonary reserve (forced vital capacity less than 80% with hemoglobin greater than 14 gm/dl or forced vital capacity less than 65% with hemoglobin less than or equal to 14 gm/dl). Cox proportional hazards model analysis confirmed these results. Different combinations of variables led to markedly different survival rates. The poorest prospects for survival were in patients with SSc who were less than or equal to 64 years old with a hemoglobin level less than or equal to 11 gm/dl, and in those greater than 64 years old with a blood urea nitrogen level greater than 16 mg/dl. These results may be useful in predicting individual patients at risk for shortened survival.

[1]  M R Segal,et al.  A comparison of estimated proportional hazards models and regression trees. , 1989, Statistics in medicine.

[2]  A. Silman,et al.  An epidemiological study of scleroderma in the West Midlands. , 1988, British journal of rheumatology.

[3]  S. Jimenez,et al.  Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. , 1988, Seminars in arthritis and rheumatism.

[4]  A. Masi,et al.  Prognostic importance of cardiac arrhythmias in systemic sclerosis. , 1988, The American journal of medicine.

[5]  Mark R. Segal,et al.  Regression Trees for Censored Data , 1988 .

[6]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[7]  G. Littlejohn,et al.  A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. , 1988, The Journal of rheumatology.

[8]  E. Hurd,et al.  Scleroderma and scleroderma-like disorders. , 1986, Seminars in arthritis and rheumatism.

[9]  N. Fineberg,et al.  Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. , 1985, American heart journal.

[10]  Neuberger Js,et al.  Epidemiology of the rheumatic diseases. , 1984 .

[11]  M. Hochberg,et al.  Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. , 1984, The American journal of medicine.

[12]  J. Rice,et al.  Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants. , 1983, Arthritis and rheumatism.

[13]  A. Masi Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[14]  E. Tan,et al.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. , 1980, Arthritis and rheumatism.

[15]  A. Masi,et al.  The epidemiology of systemic sclerosis (scleroderma) among male U.S. veterans. , 1978, Journal of chronic diseases.

[16]  N. Rowell The prognosis of systemic sclerosis , 1974 .

[17]  A. Masi,et al.  Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. , 1973, Journal of chronic diseases.

[18]  P. Holt,et al.  Survival in scleroderma. , 1971, Annals of the rheumatic diseases.

[19]  A. Masi,et al.  Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. , 1971, Annals of internal medicine.

[20]  A. Masi,et al.  Epidemiology of systemic sclerosis (scleroderma). , 1971, Annals of internal medicine.

[21]  A. Masi,et al.  Epidemiology of fatal systemic sclerosis (diffuse scleroderma). A 15-year survey in Baltimore. , 1967, Annals of internal medicine.

[22]  R. Winkelmann,et al.  Diffuse systemic scleroderma. A comparison with acrosclerosis. , 1962, Annals of internal medicine.

[23]  R. Winkelmann,et al.  Systemic scleroderma, A clinical study of 727 cases. , 1961, Archives of dermatology.

[24]  E. Hines,et al.  Prognostic Significance of Raynaud's Phenomenon and Other Clinical Characteristics of Systemic Scleroderma: A Study of 271 Cases , 1960, Circulation.